A Prospective, Interventional, Multicenter, Post marketing Clinical Study of fixed dose combination of FLUCOLD TABLET (Paracetamol 500 mg + Phenylephrine HCL 10 mg + Chlorpheniramine maleate 2 mg) Uncoated tablet of Wallace Pharmaceutical Pvt. Ltd., in the Treatment of common cold and flu syndrome in adult population.

Wallace Pharmaceuticals Pvt Ltd0 个研究点目标入组 199 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•1.Male or Female having the age of 18 to 55 years.
•2.Presented symptoms of recent onset, for more than 6 hours and less than 72 hours, characterizing one of the following conditions:
•The common cold, which consists of at least 2 symptoms among the 10 following: sneezing, rhinorrhea, nasal congestion, headache, muscle pain, discomfort in the throat, sore throat, dysphonia, cough, fever, the latter being of moderate to severe intensity through a symptom severity scale of 4 points
•3. Willing to provide written informed consent for participation in the study and adhere to the protocol requirements.

•1.Patients who are not willing to give written informed consent.
•2.Any known hypersensitivity to the study products.
•3.Pregnant and lactating women.
•4.Any history of seasonal or perennial allergic rhinitis.
•5.Patients who have taken treatment for the presenting symptom within 7 days of screening.
•6.Any history of drug abuse /chronic alcoholism
•7.Use of monoamine oxidase inhibitors or barbiturates
•8.Use of Vitamin C/ascorbic acid or taking supplements or fruits rich in vitamin C.

发起方

Wallace Pharmaceuticals Pvt Ltd